Pfizer (PFE) Research & Development (2009 - 2026)

Pfizer has disclosed Research & Development across 18 years of filings, most recently posting $2.5 billion for Q1 2026.

• In Q1 2026, Research & Development rose 13.03% year-over-year to $2.5 billion; the TTM figure through Mar 2026 stood at $10.7 billion (up 7.35% YoY), while the FY2025 annual figure was $10.4 billion, down 3.56% from the prior year.
• Research & Development declined to $2.5 billion in Q1 2026, from $3.2 billion in the prior quarter.
• Over the last five years, Research & Development for PFE reached as high as $3.2 billion in Q4 2025 and fell as low as $2.2 billion in Q1 2025.
• The 5-year median for Research & Development is $2.6 billion (2024), against an average of $2.6 billion.
• Annual changes were most pronounced in 2022 — Research & Development climbed 25.73% — and 2025, when it declined 11.63%.
• A 5-year view of Research & Development shows it stood at $2.7 billion in 2022, then gained by 4.41% to $2.8 billion in 2023, then fell by 7.71% to $2.6 billion in 2024, then increased by 23.4% to $3.2 billion in 2025, then decreased by 22.33% to $2.5 billion in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $2.5 billion, $3.2 billion, and $2.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.